![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Preview
A variety of prognostic factors that offer guidelines for adjuvant systemic therapy must be confronted by breast cancer patients and their physicians. However, many questions regarding the most effective approach remain unanswered. In this article, the authors examine this complex field and review recommendations for posttreatment follow-up.
Additional information
Notes on contributors
Lloyd D. Berkowitz
Lloyd D. Berkowitz, MD Dr Berkowitz is a medical oncologist, Center for Breast Care/Lynn Regional Cancer Center, Boca Raton Community Hospital, Boca Raton, Florida. His interests include treatment of advanced lung cancer and testicular cancer and adjuvant therapy for lung cancer.
Neil Love
Neil Love, MD Dr Love is clinical associate professor of medicine, division of hematology and oncology, University of Miami School of Medicine.